covaxin

	DCGI approves market authorisation for SII's Covid vaccine Covovax as heterologous booster dose Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. published on : 17th January 2023
	Hesitancy, short supply dent vaccination coverage in TN State has run out of Corbevax that is administered on kids belonging to 12-14 age group published on : 29th December 2022
	Vax deal: Karnataka HC relief for Bharat Biotech Justice M Nagaprasanna said Writ petition for recovery of money by a private entity from another private entity arising out of a private contract cannot be entertained. published on : 11th December 2022
	Government: Reports of forced nod to Covaxin misleading In a statement, the health ministry said that there had been media reports claiming that Bharat Biotech “had to skip certain processes” and “speed” up clinical trials due to political pressure. published on : 18th November 2022
	'Targeted narrative': Govt, Bharat Biotech deny political pressure led to Covaxin's early approval In a statement, the health ministry said that there had been media reports claiming that Bharat Biotech “had to skip certain processes” and “speed” up clinical trials due to political pressure. published on : 17th November 2022
	50 million doses of Covaxin set to expire in early 2023 due to poor demand Due to lack of product demand, production stoppage of Covaxin- a two-dose jab, was initiated by Bharat Biotech earlier in 2022. published on : 6th November 2022
	Government nod for Corbevax as booster for adults vaccinated with Covishield, Covaxin soon The approval will be based on the recommendations made by the COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) last week. published on : 10th August 2022
	Govt panel recommends Corbevax as booster for adults vaccinated with Covishield, Covaxin India's first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to inoculate children in the age group of 12 to 14 years. published on : 2nd August 2022
	Covaxin booster safe, necessary as it ensures persistent immunity: ICMR study The study said that the administration of the third dose of BBV152 increased neutralisation titers against both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, Delta Plus and Omicron) published on : 18th July 2022
	NTAGI panel recommends use of Covid vaccines Corbevax, Covaxin for kids aged 5-12 years However, there was no decision on introducing these vaccines in the vaccination programme. published on : 9th July 2022
	Covaxin booster dose generates 25-fold rise in antibodies: ICMR study The year-long longitudinal cohort study started in January last year and continued till March this year. A total of 304 healthcare workers (HCWs) were included in the study. published on : 7th July 2022
	Immunisation body likely to consider Corbevax as booster for those jabbed with Covishield, Covaxin The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. published on : 27th June 2022
	DCGI to review Serum Institute's applications for Covovax use in kids aged 2 to 7 yrs, 7 to 11 yrs The expert panel in its last meeting in April had sought more data from SII following its application seeking the emergency use authorization of Covovax for seven to 11 years. published on : 23rd June 2022
	‘Covaxin booster improves efficacy against two variants’: Bharat Biotech A booster dose of Covaxin enhances vaccine effectiveness against Delta and Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech said. published on : 16th June 2022
	Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, find ICMR study The findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer reviewed. published on : 15th June 2022
	NTAGI to discuss allowing Corbevax as booster for those vaccinated with Covishield, Covaxin: Sources The Drugs Controller General of India (DCGI) on Sunday approved Corbevax for the precaution dose for those aged 18 and above. published on : 7th June 2022
	Germany to recognise Covaxin for travel purpose from June 1, says envoy In November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin. published on : 26th May 2022
	FDA lifts hold on Covaxin's clinical trials in US The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab. published on : 24th May 2022
	Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old Presently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose. published on : 4th May 2022
	Bharat Biotech's Covaxin gets emergency approval for 6-12 age group The company said it conducted clinical trials in the paediatric population between June 2021 to September 2021 and results have shown robust safety, reactogenicity, and immunogenicity. published on : 26th April 2022